{'fraction_non_alphanumeric': 0.02358974358974359, 'fraction_numerical': 0.013333333333333334, 'mean_word_length': 5.506666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
DLEU2 participates in lymphovascular invasion and inhibits cervical cancer cell proliferation, migration, and invasion.

AIMS
To investigate the roles of deleted in lymphocytic leukemia-2 (DLEU2) in the pathology of cervical cancer.


METHODS
Differentially expressed long non-coding RNAs between cervical cancerous and para-cancerous tissues were examined in 26 clinical specimens by microarray analysis and quantitative real-time PCR. DLEU2 expression was correlated with clinical features in 108 patients with cervical cancer. The effects of DLEU2 on growth, proliferation, migration, and invasion were examined in cervical cancer cells.


RESULTS
DLEU2 was correlated with lymphovascular invasion in patients with cervical cancer. DLEU2 overexpression inhibited cell proliferation, migration, and proliferation, and colony formation in cervical cancer cells.


CONCLUSION
DLEU2 is involved in the pathology of cervical cancer, and it may be a target for clinical therapy.